Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00667004 · ClinicalTrials.gov registry record · Phase 2
Efficacy Study of Ecabet Ophthalmic Solution in Dry Eye Disease
A Phase 2 study of Dry Eye Disease, sponsored by Bausch & Lomb Incorporated.
- Completed
- Registry status
- Phase 2
- Development phase
- 183
- Enrollment target
- 1
- Study location
NCT00667004: Completed Phase 2 study of Dry Eye Disease, sponsored by Bausch & Lomb Incorporated.
NCT00667004 is a Phase 2 study of Dry Eye Disease that has completed, run by Bausch & Lomb Incorporated. The registered enrollment target is 183 participants, below the 249-participant average among 33 other Dry Eye Disease trials with a reported enrollment target (27% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00667004, a Phase 2 study of Dry Eye Disease, has completed, sponsored by Bausch & Lomb Incorporated.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 183 participants
- Enrollment target
- 1
- Study location
Study Summary
Efficacy study of ecabet ophthalmic solution in dry eye disease
Primary Outcome
The Schirmer's test is used determine if tear glands produce enough tears to keep eyes adequately moist. Calibrated strips of a non-toxic filter paper are used. One free end is placed within the lower eyelid. At the conclusion of the test, the paper strip is removed from the lower eyelid and the amount of wetting of the paper strip is measured.
Conditions Studied
Interventions
- DRUG placebo
- DRUG ecabet ophthalmic solution
Study Locations (1)
California
- ISTA Pharmaceuticals, Inc. - Irvine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 183 participants |
| Start Date | 2008-03-22 |
| Est. Completion | 2008-09-12 |
| Phase | Phase 2 |
What the finished NCT00667004 record still lists
NCT00667004 is an interventional study that assigns participants to a tested intervention. The registered 183 participants enrollment target is mid-sized for trials with a published cap, below the 249-participant average among 33 other Dry Eye Disease trials with a reported enrollment target (27% lower).
The record links to 1 condition, with Dry Eye Disease appearing as the primary indexed condition, and to 2 interventions - of which placebo is the first listed.
NCT00667004 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT00667004 about?
NCT00667004 is a clinical study titled "Efficacy Study of Ecabet Ophthalmic Solution in Dry Eye Disease". Efficacy study of ecabet ophthalmic solution in dry eye disease
What is the current status of trial NCT00667004?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 183 participants. The study started on 2008-03-22. Estimated completion is 2008-09-12.
What conditions does trial NCT00667004 study?
This clinical trial studies the following conditions: Dry Eye Disease.
What interventions are being tested in trial NCT00667004?
The interventions under investigation include: placebo (DRUG), ecabet ophthalmic solution (DRUG).
Who is sponsoring clinical trial NCT00667004?
This trial is sponsored by Bausch & Lomb Incorporated, which has 174 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00667004 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Dry Eye Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00667004's enrollment target sits among peer trials
183 17th of 33 higher than 17 of 33 other Dry Eye Disease trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Dry Eye Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Evaluating the Safety, Tolerability, and Efficacy of GRF312 5% in Participants With Dry Eye Disease (DED).
RECRUITING · Phase 2
-
A Study Evaluating the Safety and Efficacy of a Fixed-Dose Combination for Dry Eye Disease
RECRUITING · Phase 2
-
Phase 2b Controlled Study
ACTIVE NOT RECRUITING · Phase 2
-
A Study of TL-925 Ophthalmic Emulsion as a Treatment for Dry Eye Disease
ACTIVE NOT RECRUITING · Phase 2
-
The Study Evaluating the Efficacy and Safety of OK-101 in Subjects With Dry Eye Disease
COMPLETED · Phase 2
-
A Study of TL-925 as a Treatment for Dry Eye Disease
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03859297 · 183 participants · NA
Mechanisms of Rumination Change in Adolescent Depression
- NCT04270591 · 183 participants · Phase 1
Assessment of Anti-tumor and Safety in Glumetinib in Patients With c-MET-positive Non-Small Cell Lung Cancer
- NCT06764615 · 183 participants · Phase 2
A Continuation Study of TAK-279 in Adults With Ulcerative Colitis (UC) and Crohn's Disease (CD)
- NCT06872684 · 183 participants · NA
Safety and Efficacy of Endovascular Treatment of Intracranial Aneurysms With Surpass Elite With GUARDian Flow Diverter (GUARD)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI